Thus, we reported the first case of indolent SM that was successfully treated with montelukast, IFN-α-2a, and methylprednisolone in a child.
INTRODUCTION
M astocytosis refers to a group of myeloproliferative disorders characterized by excessive proliferation and accumulation of mast cells (MCs) in tissues. It is rare in both adults and children and occurs in <0.01% of the general population. [1] The most common form of mastocytosis in the pediatric population is cutaneous mastocytosis (CM), in which the MC hyperplasia occurs in the skin. Systemic mastocytosis (SM) is a rare, heterogeneous, and progressive disease, characterized by the accumulation of atypical MCs in various organ systems with or without skin involvement. [2] Treatment of CM is still based on symptomatic treatment as most of the pediatric cases are known to resolve spontaneously by puberty. No standard treatment exists for SM. Histamine receptor antagonists, proton pump inhibitors, corticosteroids, interferon (IFN), and oral cromolyn sodium are recommended as the basis of the therapy. [1] and proximal extremities and noticeably her face, palms, and soles with a positive Darier's sign. She has hepatosplenomegaly but no palpable peripheral lymphadenopathy. A preliminary blood test revealed an elevated serum tryptase level (356 ng/ml), and normal blood count, renal function, and liver function.
Bone marrow aspiration showed infiltration by MCs (rate >10%) [ Figure 1 ]. Flow cytometry of bone marrow sample revealed that there was CD117/CD25 positivity of 18.4% and CD117/CD2 positivity of 0.7% [ Figure 2 ]. A punch biopsy confirmed the diagnosis of mastocytosis.
Diagnosis of SM was verified by one major and one minor WHO criteria: Presence of multifocal dense aggregates of MCs in bone marrow (major criteria) and confirmed by expression of CD2, CD25, and CD117 in bone marrow (minor criteria). Our patient was diagnosed as indolent SM because of high serum tryptase level, organomegaly, and infiltration of MCs in the bone marrow.
During follow-up, systemic anaphylaxis was determined and treated for 3 times. We recommended the self-administration of epinephrine on demand for anaphylactoid episodes. Montelukast (0.3 mg/kg/day) was given to relieve symptoms of prevent anaphylaxis. IFN-α-2a (0.15 MU/kg/day) and methylprednisolone (2 mg/kg/day) were added to the treatment for SM. It was planned to maintain low-dose methylprednisolone therapy for 12 months and to withdraw gradually after 11 months.
Treatment with montelukast, IFN-α-2a, and methylprednisolone resulted in symptom improvement and sustained reduction of her symptoms, cutaneous lesion, and tryptase level [ Figure 3 ]. Anaphylactic reactions have never repeated after treatment.
DISCUSSION
Mastocytosis is diagnosed on the basis of history, clinical manifestations, and histopathology and laboratory evaluation. Bone marrow is the most common extracutaneous site involved by SM, and bone marrow biopsy or bone marrow aspiration is preferable for morphologic diagnosis. [1] In our patient's bone marrow aspiration, there were multifocal, dense aggregates of MCs. SM is very rare in pediatric population. Hannaford and Rogers described 173 pediatric cases of mastocytosis; only two of them which were systemic disease. [3] The symptoms -bone marrow infiltration and hepatosplenomegaly -are strong evidence for SM in our patient. to recurrent systemic symptoms (e.g., flushing, palpitations, dyspepsia, diarrhea, bone pain) that can be severe and potentially life-threatening (anaphylaxis). [4, 5] The patient was considered as indolent SM, because she has urticaria pigmentosa-like cutaneous lesions and anaphylaxis for 3 times. Anaphylaxis which caused induced massive degranulation of MC is the most important manifestation and it is particularly seen in the patient with SM and it is not rarely seen. [6, 7] We recommended the self-administration of epinephrine to the patient on demand for anaphylactoid episodes.
The WHO diagnostic major criterion for SM includes multifocal, dense aggregates of MCs (15 or more) detected in sections of bone marrow and confirmed by tryptase immunohistochemistry or other special stains, whereas minor criteria are as follows: (a) In biopsy section, more than 25% of the MCs in the infiltrate have atypical morphology or of all the MCs in the aspirate smear, more than 25% are immature or atypical; (b) MCs co-express CD117 with CD2 and/or CD25; (c) detection of KIT point mutation at codon 816 in bone marrow, blood, or other extracutaneous organs; (d) serum total tryptase persistently > 20 ng/mL (not a valid criterion in cases of SM with associated clonal hematologic non-MC lineage disease. [4] Immunohistochemistry and flow cytometry immunophenotypic analysis are commonly used methods for diagnosing and monitoring patients with SM. Antibodies specific for tryptase and CD117 are most widely used and are useful for highlighting MCs. [8, 9] Aberrant expression of CD2 or CD25 by MCs in the bone marrow is more useful for diagnosis because both antigens are not expressed in normal or reactive MCs whereas neoplastic MCs. CD 117 also used to distinguish SM from CM. The diagnosis of our SM patient was verified by one major and one minor WHO criteria: Presence of multifocal, dense aggregates of MCs in bone marrow (major criteria) and confirmed by expression of CD2, CD25, and CD117 in bone marrow (minor criteria). [4] We used combined therapy (IFN-α-2a, methylprednisolone, and montelukast) to reduce progressive symptoms. IFN-α as the first-line cytoreductive agent, is effective for relieving mediator release and gastrointestinal symptoms, skin rash, osteoporosis, cytopenias, ascites, and hepatosplenomegaly. Systemic corticosteroids can be used to control severe mediator-related symptoms. Systemic steroids are also employed with IFN-α in cytoreductive therapy. The use of chemotherapy, including kinase inhibitors, is strongly discouraged unless severe hematologic disease is present since malignant evolution is extremely rare. [1, 9] Imatinib role in the treatment of indolent and CM is less well established. [10] CONCLUSION SM, the rarest form of mastocytosis in pediatric population, is often misdiagnosed as atopic dermatitis or other dermatological disorders with itchy lesions. This patient has been treated successfully with combination therapy. Further studies are needed to develop new therapeutic approaches for pediatric SM.
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